The patient's ability to tolerate surgery without significant morbidity is an factor in triaging advanced epithelial ovarian cancer patients for initial surgical management. Indeed, the clinician could use this information to personalize decisions regarding upfront surgical cytoreduction versus neoadjuvant chemotherapy.